Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03898791 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
A Phase 1 study of Small-cell Lung Cancer, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 20
- Study locations
NCT03898791: Completed Phase 1 study of Small-cell Lung Cancer, sponsored by Eli Lilly and Company.
NCT03898791 is a Phase 1 study of Small-cell Lung Cancer that has completed, run by Eli Lilly and Company. The registered enrollment target is 48 participants, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03898791, a Phase 1 study of Small-cell Lung Cancer, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
Primary Outcome
Number of Participants with Dose Reductions
Conditions Studied
Interventions
- DRUG LY3295668 Erbumine
Study Locations (20)
Texas
- Texas Oncology Cancer Center - Austin
- Texas Oncology Fort Worth - Fort Worth
- University of Texas MD Anderson Cancer Center - Houston
- US Oncology - The Woodlands
- Tyler Cancer Center - Tyler
Other
- Grand Hopital de Charleroi-Site Notre-Dame - Charleroi
- Universitair Ziekenhuis Gent - Ghent
- Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - Leuven
- AZ Delta - Roeselare
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Arkansas
- Highlands Oncology Group - Fayetteville
Colorado
- Rocky Mountain Cancer Center - Denver
Florida
- H Lee Moffitt Cancer Center - Tampa
Missouri
- Washington University Medical School - St Louis
New Hampshire
- Dartmouth Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2019-07-16 |
| Est. Completion | 2021-03-30 |
| Phase | Phase 1 |
What the finished NCT03898791 record still lists
NCT03898791 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which LY3295668 Erbumine is the first listed.
NCT03898791 names 20 study sites across 12 states, led by Texas, Other, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03898791 about?
NCT03898791 is a clinical study titled "A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer". The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
What is the current status of trial NCT03898791?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2019-07-16. Estimated completion is 2021-03-30.
What conditions does trial NCT03898791 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT03898791?
The interventions under investigation include: LY3295668 Erbumine (DRUG).
Who is sponsoring clinical trial NCT03898791?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03898791 being conducted?
This trial has 20 study locations across Arkansas, Colorado, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03898791's enrollment target sits among peer trials
48 53rd of 79 higher than 27 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI